Boehringer Ingelheim has launched a new fund to invest in companies that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science.
The Boehringer Ingelheim Venture Fund (BIVF) will initially invest a total fund volume of €100 million.
“Our investments will extend beyond the current therapeutic area focus of Boehringer Ingelheim and our existing therapeutic approaches and technologies,” said Prof. Andreas Barner, Chairman of the Board of Managing Directors at Boehringer Ingelheim.
“We have extensive drug discovery expertise and can take advantage of knowledge and experience available within our global organisation, but we are aware that there is an entire landscape of novel therapeutic ideas and potentially breakthrough technologies that need to be supported for future patients’ benefit.”
The BIVF will invest in companies that provide, for example, new therapeutic concepts including stem cells and RNA silencing as well as new generation vaccines, new generation protein or antibody technologies, new molecular targets and/or first-in-class lead compounds.
“By focusing on novel therapeutic concepts and potentially breakthrough technologies, our Venture Fund represents a long-term investment in external innovation,” added Dr Michel Pairet, Head of the Boehringer Ingelheim Venture Fund. “Our philosophy is to provide both our expertise and funding to drive innovative ideas from early stages into clinical testing.”